[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hemodynamic-map-stability\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hemodynamic-map-stability":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,66,100],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100629916","phase-3-effect-of-adding-a-low-dose-epinephrine-bolus-prior-to-infusion-on-maternal-hemodynamic-stability-during-cesarean-section-100629916",false,"NCT07480889","Effect of Adding a Low-Dose Epinephrine Bolus Prior to Infusion on Maternal Hemodynamic Stability During Cesarean Section","Effect of Adding a Low-Dose Epinephrine Bolus Prior to Infusion on Maternal Hemodynamic Stability During Cesarean Section Under Spinal Anesthesia: A Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age: 18 to 35 years.\n2. American Society of Anesthesiologists (ASA) physical status II.\n3. Undergoing Elective Lower Segment Cesarean Section under Spinal Anesthesia.\n\nExclusion Criteria:\n\n1. Uncontrolled cardiac morbidities as reduction of ejection fraction\\\u003C 60%, History (within 3months) of myocardial infarction, cerebrovascular accident, transient ischemic attacks or coronary artery disease\u002Fstents\n2. Poorly controlled Hypertensive disorders of pregnancy\n3. Peripartum bleeding\n4. Multiple pregnancies (e.g., twin gestations)\n5. Coagulation disorders defined as platelet count \\\u003C100,000\u002FμL, INR \\>1.4, or known inherited clotting factor deficiency.\n6. Baseline systolic blood pressure (SBP) \\\u003C 100 mmHg or \\>130 mmHg\n7. Refusal of patients.","FEMALE","18 Years","35 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","In North America, norepinephrine, ephedrine, and epinephrine have been recommended as first-choice vasopressors for the treatment of spinal hypotension during cesarean delivery. However, in international consensus guidelines, epinephrine was recommended for circulatory collapse only. Phenylephrine infusion is an important therapeutic strategy for preventing spinal-induced hypotension (SIH) in cesarean delivery, as it decreases the incidence of hypotension, nausea, and vomiting. However, high doses may reduce maternal heart rate and cardiac output in a dose-dependent manner.\n\nEphedrine, previously considered the first-choice drug, has both α and β receptor agonistic activity and causes norepinephrine release from sympathetic neurons. Its β1 effect increases heart rate and contractility, but may cause undesirable tachycardia. Tachyphylaxis can develop with repeated doses. Norepinephrine, the biosynthetic precursor of epinephrine, has both potent α and weak β agonist effects, tending to cause bradycardia.\n\nDespite a lower incidence of hypotension with prophylactic norepinephrine, PSH still occurs in up to 30% of parturients undergoing cesarean section. The administration of a bolus dose of epinephrine prior to continuous infusion is an unusual practice in obstetric anesthesia, but has been reported to be safe in other contexts and in pregnant women when used for hemodynamic support.\n\nEpinephrine has both potent α- and β-adrenoceptor agonist activity. Its β effects could offset reflex decreases in maternal HR and CO during spinal anesthesia for cesarean delivery. Although some studies compared epinephrine infusion with phenylephrine, it remains unclear whether adding an initial bolus of epinephrine before infusion offers superior maternal hemodynamic stability compared to infusion alone.",[27],"Hemodynamic (MAP) Stability","RECRUITING","2026-03-19",{"date":31,"type":32},"2026-03-23","ACTUAL",{"date":34,"type":32},"2026-03-18",{"date":36,"type":21},"2026-06",{"name":38,"class":39},"Cairo University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":40},"100621095","hemodynamic-optimization-using-an-artificial-intelligenze-system-100621095","NCT07366164","Hemodynamic Optimization Using an Artificial Intelligenze System","The Assisted Fluid Management For High-Risk Patients During Colorectal Surgery: A Randomised Controlled Clinical Trial","SIMPLY","Inclusion Criteria:\n\n\\- patients \\>18 years old and ASA 3 scheduled for laparoscopic colorectal surgery\n\nExclusion Criteria:\n\n* Refusal of consent\n* Body Mass Index \\> 35 kg\u002Fm2\n* urgent cases\n* pregnancy","ALL",{"count":51,"type":21},80,[53],"NA","This study will investigate the impact of using an automated fluid management system on intraoperative fluid therapy in patients undergoing colorectal surgery. The aim is to evaluate whether automated guidance can optimize hemodynamic stability and reduce the incidence of arterial hypotension,",[27,56],"Fluid Management","2026-01-16",{"date":59,"type":32},"2026-01-26",{"date":61,"type":32},"2025-10-01",{"date":63,"type":21},"2027-01-01",{"name":65,"class":39},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":84,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":40},"100617148","using-artificial-intelligence-to-guide-fluid-therapy-during-major-cancer-surgery-a-randomized-controlled-trial-100617148","NCT07314853","Using Artificial Intelligence to Guide Fluid Therapy During Major Cancer Surgery: A Randomized Controlled Trial","Fluid Optimization in Cancer Surgery With AI-Assisted Management - FOCUS-AFM Trial","FOCUS-AFM","Inclusion Criteria:\n\n* Age ≥ 18 years\n* American Society of Anesthesiologists (ASA) Physical Status II-IV\n* Undergoing major abdominal oncologic surgery (open or laparoscopic) with an expected duration \\>2 hours\n* Planned invasive arterial pressure monitoring\n* Ability to understand and sign informed consent\n\nExclusion Criteria:\n\n* Significant arrhythmias (e.g., persistent atrial fibrillation)\n* Severe aortic stenosis\n* Emergency surgery\n* Sepsis\n* End-stage renal disease on dialysis\n* Pregnancy\n* Impossibility to cannulate the radial artery\n* Refusal to participate or refusal of data processing consent",{"count":75,"type":21},176,[53],"The goal of this clinical trial is to learn if using artificial intelligence to guide intravenous fluid therapy during major cancer surgery can help keep blood pressure more stable compared with usual care in adult patients undergoing major cancer surgery. The main questions it aims to answer are:\n\n* Does artificial intelligence-guided fluid therapy reduce hypotensive events during surgery?\n* Does this approach improve recovery and reduce complications after major cancer surgery?\n\nResearchers will compare artificial intelligence-guided fluid therapy with standard fluid management to see if the artificial intelligence-guided approach provides better support during surgery.\n\nParticipants will:\n\n* Undergo major cancer surgery under general anesthesia\n* Receive either artificial intelligence-guided fluid management or standard fluid management during surgery\n* Be monitored during and after surgery as part of routine clinical care\n* Be followed after surgery to assess recovery and possible complications",[79,80,27,81,82,83],"Neoplasm","Cancer","Cancer Surgery","Artificial Intelligence (AI)","Fluid Therapy DURING SURGERY",[85,86,87,88,89],"randomized controlled trial","cancer","fluid balance","fluid therapy","artificial intelligence","NOT_YET_RECRUITING","2026-01-07",{"date":93,"type":32},"2026-01-09",{"date":95,"type":21},"2026-02",{"date":97,"type":21},"2029-02",{"name":99,"class":39},"National Cancer Institute, Naples",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":49,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":40},"100587753","delta-variation-to-guide-hemodynamic-optimization-100587753","NCT06932484","Delta Variation to Guide Hemodynamic Optimization","A NEW APPROACH IN THE MANAGEMENT OF INTRAOPERATIVE ARTERIAL HYPOTENSION BASED ON DELTA VARIATION OF HEMODYNAMIC PARAMETERS: A RANDOMISED CLINICAL TRIAL","DELTA","Inclusion Criteria: All patients \\> 18 years old scheduled for major abdominal\n\nExclusion Criteria:\n\nBody Mass Index \\> 35 kg\u002Fm2 Pregnancy Refusal to sign written informed consent Urgent and\u002For emergency surgery",{"count":109,"type":21},104,[53],"intraoperative hemodynamic optimization will be based on the percentage of variation of the parameters",[113],"Hemodynamic MAP Stability","2025-07-30",{"date":116,"type":32},"2025-07-31",{"date":118,"type":32},"2025-06-01",{"date":120,"type":21},"2027-06-01",{"name":65,"class":39}]